Proliferation-Guided Risk Stratification in HER2-Low vs. HER2-Positive Hormone Receptor-Positive Breast Cancer: A Multicenter Retrospective Analysis [0.03%]
HER2低阳性与HER2阳性激素受体阳性乳腺癌的增殖指导性风险分层：一项多中心回顾性分析
Sait Kitapli,Özgür Tanriverdi,İsmail Bayrakci et al.
Sait Kitapli et al.
Background: HER2-low breast cancer is a newly characterized subgroup with unclear prognostic implications. This study investigates the prognostic role of Ki67 in hormone receptor-positive (HR+) HER2-low and HER2-positive ...
Frontline pembrolizumab or methotrexate in elderly, frail, or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-HNSCC) - results of the randomized phase 2 study ELDORANDO (AIO-KHT-0115) [0.03%]
老年、体弱或不适合顺铂治疗的复发性或转移性头颈部鳞状细胞癌患者中帕博利珠单抗与甲氨蝶呤疗效的随机II期研究(ELDORANDO，AIO-KHT-0115)
Konrad Klinghammer,Ullrich Graeven,Philipp Ivanyi et al.
Konrad Klinghammer et al.
Background Elderly, frail, or cisplatin-ineligible patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) have a poor prognosis. To date, no standard of care has been defined for this population. Meth...
TACE Combined with Hepatic Arterial Infusion of Nivolumab for Inhibiting Tumor Angiogenesis in Hepatocellular Carcinoma [0.03%]
经肝动脉灌注纳武单抗联合肝癌TACE抑制肿瘤血管生成作用研究
Sujing Zhang,Zheng Zheng,Changwang Zhang et al.
Sujing Zhang et al.
Objective: This study aims to explore the clinical efficacy of transarterial chemoembolization (TACE) combined with the immune checkpoint inhibitor nivolumab administered via hepatic arterial infusion (HAI) in inhibiting ...
Adverse effects and functional outcome after salvage lymph node dissection in prostate cancer [0.03%]
挽救性盆腔淋巴结清扫术的并发症及功能预后
Ruth Himmelsbach,Julia Franz,August Sigle et al.
Ruth Himmelsbach et al.
Introduction: To generate a standardized assessment of postoperative complications and functional results in patients undergoing salvage lymph node dissection (sLND) in a multi-modal setting with prior primary therapy and...
Anti-HER2/Neu Antibody Therapy Inhibits HER2+ Breast Cancer by Blocking Myeloid-Derived Suppressor Cell Activity [0.03%]
抗HER2 / Neu抗体治疗通过阻断髓样衍生抑制细胞活性来抑制HER2阳性乳腺癌
Jae-Hyeog Choi,Saegwang Park,Xingguo Quan et al.
Jae-Hyeog Choi et al.
Background: Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population playing a key role in tumor-related immune suppression. MDSCs are immature cells with myeloid markers CD11b and Gr1 in mice and accumulat...
Treatment Navigation in Breast Cancer Management: Process Cost Analysis Based on German Case Studies [0.03%]
基于德国病例研究的乳腺癌治疗导航流程成本分析
Jasmin Nachtigall,Ann-Cathrine Froitzheim,Melina Sophie Kurte et al.
Jasmin Nachtigall et al.
Introduction: The high incidence of breast cancer combined with the growing number of innovative and complex treatment options, such as oral tumor therapies, is increasingly shifting oncological care to the outpatient sec...
Machine learning-based prognostic modeling of seven signatures associated with lysosomes for predicting prognosis and immune status in clear cell renal cell carcinoma [0.03%]
基于机器学习的七种与溶酶体相关的特征的预后模型构建，用于透明细胞肾细胞癌的预后和免疫状态预测
Jie Chen,Bo Chen,Mengli Zhu et al.
Jie Chen et al.
Background: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer and is associated with poor prognosis in advanced stages. This study aims to develop a prognostic model for patients with ccR...